TCF3 (Transcription Factor 3)

P1, N=10, Completed, Zhejiang University | Recruiting --> Completed | N=16 --> 10 | Trial completion date: Aug 2025 --> May 2025 | Trial primary completion date: Aug 2025 --> May 2025

P1/2, N=20, Recruiting, University Hospital Tuebingen | Trial completion date: Mar 2027 --> Feb 2029 | Trial primary completion date: Mar 2027 --> Jul 2028

Furthermore, patients with TCF3::PBX1 or MEF2D fusion and high EVI1 expression had RFS and OS similar to those without the corresponding fusions, and patients with ZNF384 fusion and low EVI1 expression had RFS and OS comparable to those without ZNF384 fusions (all p > 0.05). Low EVI1 transcript levels at diagnosis are related to poor prognosis in adult Ph-negative B-ALL, and EVI1 expression may improve fusion gene-defined risk stratification.

Notably, in murine models of colorectal cancer and osteosarcoma, the TCF21-derived peptide significantly inhibits metastasis by restoring the physiological gatekeeper function of pericytes on vessels, offering a potential therapeutic strategy to target TPCs and suppress metastasis. Our findings reveal a TPC-specific transcription factor heterodimer and provide a promising pericyte-targeting strategy for preventing hematogenous metastasis.

The high diagnostic coverage and rapid turnaround of the FISH-based approach underscore its value as a reliable and efficient diagnostic tool in newly diagnosed ALL. The authors have confirmed clinical trial registration is not needed for this submission.

Our study demonstrates that Emodin induces ferroptosis through the miR-4465/NFE2L3/HMGCR/GPX4 axis in HCC, revealing NFE2L3's role in ferroptosis and suggesting Emodin as a promising therapeutic candidate.

Although accepting CAR-T and DLI treatments after HSCT, she died due to primary disease recurrent relapse. The combination of CAR-T-cell therapy before HSCT and pro-DLI treatment after HSCT may represent an effective strategy to improve outcomes in these pediatric patients.

Our findings reveal that TCF3 and SE mediate TRIB2 overexpression to inhibit ferroptosis via the KEAP1-NRF2 pathway and drive HB pathogenesis, providing potential diagnostic and prognostic markers for HB.

Cancers with high co-expression of ELF3 and HNF4A were frequently chromosomally instability (CIN), intestinal-type adenocarcinomas, and harbored TP53 mutations and WWOX deletions. Expression of E74 like ETS transcription factor 3 (ELF3), an ETS transcription family member, correlates with expression of other key factors in gastric cancer and confers specific characteristics that may become exploited in targeted therapeutic interventions.

P1/2, N=32, Active, not recruiting, Bambino Gesù Hospital and Research Institute | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2025 --> Mar 2027

We developed a hydrogel platform for the targeted 14-day release of RUNX3 pDNA by attaching hExo-Rs to gelatin using microbial transglutaminase, which enables the selective decrease in cancer cell viability and confirms apoptosis. Our demonstration of RUNX3 gene therapy with Exos presents selective anticancer effectiveness and the promise of clinical use through localized, sustained release using the hydrogel.